**Table 5 – EMA/FDA recommendation for CKD stages 4 and 5 patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | Dabigatran | Apixaban | Rivaroxaban | Edoxaban |
| eGFR 15-30 ml/min | FDA | 75 mg BID | Standard dose | 15 mg QD with the evening meal | 30 mg, 1×/d |
| EMA | Contraindicated | 2 x 2.5 mg | Limited clinical data - 15 mg daily | 30 mg |
| eGFR < 15 ml/min | FDA | Not approved | 5 or 2.5 BID | Limited clinical data – 15 mg daily | Not approved |
| EMA | Contraindicated | Contraindicated | Contraindicated | Contraindicated |
| Dialysis | FDA | Not approved | 5 or 2.5 BID | Limited clinical data – 15 mg daily | Not approved |
| EMA | Contraindicated | Contraindicated | Contraindicated | Contraindicated |